Developmental research of tailored immune-modulation therapy against refractory chronic hepatitis C.

• Project/Area Number: 19590764
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Gastroenterology
• Research Institution: Osaka University
• Principal Investigator: KASAHARA Akinori Osaka University, 医学系研究科, 准教授 (70214286)
• Co-Investigator(Kenkyū-buntansha): KANTO Tatsuya 大阪大学, 医学系研究科, 寄附講座准教授 (80372613) ; HIRAMATSU Naoki 大阪大学, 医学系研究科, 講師 (30362700)
• Project Period (FY): 2007 – 2009
• Project Status: Completed (Fiscal Year 2009)
• Budget Amount: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000); Fiscal Year 2009: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2008: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2007: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
• Keywords: C型肝炎 / ペグインターフェロンα / リバビリン / 樹状細胞 / 制御性T細胞 / 性差

Research Abstract

It is reported that approximately 50% of chronic hepatitis C patients with HCV genotype 1 and high titer are successfully treated with 48-week peg-IFN-alfa and ribavirin therapy. In this research project, we aimed to clarify how immune responses are involved in HCV eradication, and elucidate if dynamics of immune cells could serve as predictor of therapeutic response in the treatment. In monovariate analyses, pretreatment MDC frequency and DC function at the end of treatment were significantly higher in the SVR group than those in the non-SVR one. Multivariate analyses based on viral and host factors and drug adherence revealed that platelet counts and PDC frequency were independently contributed to the SVR. Therefore, "immune response-guided therapy" is rational in the establishment of a tailored treatment for chronic hepatitis C patients.

Research Products

• [Journal Article] Enhanced ability of regulatory T cells in chronic hepatitis C patients with persistently normal alanine aminotransferase levels than those with active hepatitis (2009)
  • Author(s): Itose, I., Kanto, T. Kakita, N., Takebe, S., Inoue, M., Higashitani, K., Miyazaki, M., Miyatake, H., Sakakibara, M., Hiramatsu, N., Takehara, T., Kasahara, A., Hayashi, N.
  • Journal Title: than those with active hepatitis. Journal of Viral Hepatitis 16 Pages: 846-852
  • Peer Reviewed
• [Journal Article] Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin (2009)
  • Author(s): Hiramatsu, N., Oze, T Yakushijin, T., Inoue, Y., Igura, T., Mochizuki, K., Imanaka, K., Kaneko, A., Oshita, M., Hagiwara, H., Mita, E., Nagase, T., Ito, T., Inui, Y., Hijioka, T., Katayama, K., Tamura, S., Yoshihara, H., Imai, Y., Kato, M., Yoshida, Y., THiramatsu, N., Oze, T Yakushijin, T., Inoue, Y., Igura, T., Mochizuki, K., Imanaka, K
  • Journal Title: Journal of Viral Hepatitis 16 Pages: 586-594
  • Peer Reviewed
• [Journal Article] Two types of drug-resistant hepatitis B viral strains emerging alternately and their susceptibility to combination therapy with entecavir and adefovir Antiviral Therapy (2009)
  • Author(s): Kurashige N., Ohkawa, K Hiramatsu, N., Oze, T., Yakushijin, T., Mochizuki, K., Hosui, A., Miyagi, T., Ishida, H., Tatsumi, T., Kanto, T., Takehara, T., Hayashi, N.
  • Journal Title: 14 Pages: 873-877
  • Peer Reviewed
• [Journal Article] Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders (2009)
  • Author(s): Imai, Y., Tamura, S.,. Tanaka, H., Hiramatsu, N., Kiso, Y., Doi, Y., Inada, M., Nagase, T., Kitada, T., Imanaka, K., Fukuda, K., Takehara, T., Kasahara, A., Hayashi, N.
  • Journal Title: Journal of Viral Hepatitis (in press)
  • Peer Reviewed
• [Journal Article] Molecular insights into (beta)-galactoside (alpha)2, 6-sialyltransferase secretion in vivo (2009)
  • Author(s): Kitazume, S., Oka, R. Ogawa, K., Futakawa, S., Hagiwara, Y., Takigawa, H., Kato, M., Kasahara, A., Miyoshi, E., Taniguchi, N., Hashimoto, Y.
  • Journal Title: Glycobiology 19 Pages: 479-487
  • Peer Reviewed
• [Journal Article] Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and susutained virological responses (2009)
  • Author(s): Inoue, Y., Hiramatsu, N, Oze, T., Yakushijin, T., Mochizuki, K., Hagiwara, H., Oshita, M., Mita, E., Fukui, H., Inada, M., Tamura, S., Yoshihara, H., Hyashi, E., Inoue, A., Imai, Y., Kato, M., Miyagi, T., Hohsui, A., Ishida, M., Kiso, S., Kanto, T., KasahInoue, Y., Hiramatsu, N, Oze, T., Y
  • Journal Title: Journal of Viral Hepatitis (in press)
  • Peer Reviewed
• [Journal Article] Effect of interferon alpha-2b plus ribavirine therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis (2009)
  • Author(s): Kurokawa, M., Hiramatsu, M Oze, T., Mochizuki, K., Yakushijin, T., Kurashige, N., Inoue, Y., Igura, T., Imanaka, K., Yamada, A., Oshita, M., Hagiwara, H., Mita, E., Ito, T., Inui, Y., Hijioka, T., Yoshihara, H., Inoue, A., Imai, Y., Kato, M., Kiso, S., KaKurokawa, M., Hiramatsu, M Oze, T., Mochizuki, K.
  • Journal Title: Hepatology Research 39 Pages: 432-438
  • Peer Reviewed
• [Journal Article] Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance (2009)
  • Author(s): Kurashige, N., Ohkawa K. Hiramatsu, N., Yakushijin, T., Mochizuki, K., Oze, T., Kiso, S., Kanto, T., Takehara, T., Kasahara, A., Doi, Y., Yamada, A., Fukuda, K., Oshita, M., Mita, E., Fukui, H., Nagase, T., Yoshihara, H., Imai, Y., Kato, M., Kashihara, T. Kurashige, N
  • Journal Title: Journal of Gastroenterology 44 Pages: 864-870
  • NAID: 10025176735
  • Peer Reviewed
• [Journal Article] Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders (2009)
  • Author(s): Imai, Y., Tamura, S., et al.
  • Journal Title: Journal of Viral Hepatitis (In press)
  • Peer Reviewed
• [Journal Article] Molecular insights into (beta)-galactoside (alpha) 2,6-sialyltransferase secretion in vivo (2009)
  • Author(s): Kitazume, S., Oka, R., et al.
  • Journal Title: Glycobiology 19 Pages: 479-487
  • Peer Reviewed
• [Journal Article] Enhanced ability of regulatory T cells in chronic hepatitis patients with persistently normal alanine aminotransferase levels than those with active hepatitis (2009)
  • Author(s): Itose, I., Kanto, T., et al.
  • Journal Title: Journal of Viral Hepatitis 16 Pages: 844-852
  • Peer Reviewed
• [Journal Article] Effect of interferon alpha-2b plus ribavirine therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis (2009)
  • Author(s): Kurokawa, M., Hiramatsu, M, et al.
  • Journal Title: Hepatology Research 39 Pages: 432-438
  • Peer Reviewed
• [Journal Article] Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin : reducing drug doses has no impact on rapid and susutained virological responses (2009)
  • Author(s): Inoue, Y., Hiramatsu, N, et al.
  • Journal Title: Journal of Viral Hepatitis (in press)
  • Peer Reviewed
• [Journal Article] Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance (2009)
  • Author(s): Kurashige, N., Ohkawam K., et al.
  • Journal Title: Journal of Gastroenterology 44 Pages: 864-870
  • Peer Reviewed
• [Journal Article] Repeated administration of recombinant human serum albumin caused no serious allergic reactions in patients with liver cirrhosis-a multicenter clinical study Journal of Gastroenterology (2008)
  • Author(s): Kasahara A, Kita K., Tomita E, Toyota J, Imai Y, Kumada H.
  • Journal Title: 43 Pages: 464-472
  • Peer Reviewed
• [Journal Article] Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990-2003 (2008)
  • Author(s): Tanaka H., Imai Y. Hiramatsu N, Ito Y, Imanaka K, Oshita M, Hijioka T, Katayama K, Yabuuchi I, Yoshihara H, Inoue A, Kato M, Takehara T, Tamura S, Kasahara A, Hayashi N, Tsukuma H.
  • Journal Title: Annals of Internal Medicine 148 Pages: 820-826
  • Peer Reviewed
• [Journal Article] Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: A novel approach for the development of tumor markers (2008)
  • Author(s): Nakano M., Nakagawa T. Ito T, Kitada T, Hijioka T, Kasahara A, Tajiri M, Wada Y, Taniguchi N, Miyoshi E.
  • Journal Title: nternational Journal of Cancer 122 Pages: 2301-2309
  • Peer Reviewed
• [Journal Article] Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C (2008)
  • Author(s): iramatsu N, Kurashige N, Oze T, Takehara T, Tamura S, Kasahara A, Oshita M, Katayama K, Yoshihara H, Imai Y, Kato M, Kawata S, Tsubouchi H, Kumada H, Okanoue T, Kakumu S, Hayashi N.
  • Journal Title: Hepatology Research 38 Pages: 52-59
  • NAID: 10020116973
  • Peer Reviewed
• [Journal Article] Impaired cytokine response in myeloid dendritic cells in chronic hepatitis C virusinfection regardless of enhanced expression of Toll-like receptors and retinoic acid inducible gene-I Journal of Medical Virology (2008)
  • Author(s): Miyazaki M., Kanto T., Inoue, M., Itose, I., Miyatake, H., Sakakibara, M., Yakushijin, T., Kakita, N., Hiramatsu, N., Takehara, T., Kasahara, A., Hayashi, N.
  • Journal Title: 80 Pages: 980-988
  • Peer Reviewed
• [Journal Article] new prognostic system for hepatocellular carcinoma including recurrent cases: a study of 861 patients in a single institution (2008)
  • Author(s): Toyama T., Hiramatsu N. Yakushijin, T., Oze, T., Nakanishi, F., Yasumaru, M., Mochizuki, K., Kanto, T., Takehara, T., Kasahara, A., Hayashi, N.
  • Journal Title: Journal of Clinical Gastroenterology 42 Pages: 317-322
  • Peer Reviewed
• [Journal Article] Initial viral response is the most powerful predictor of the emergence of YMDD mutant virus in chronic hepatitis B patients treated with lamivudine (2008)
  • Author(s): Kurashige N., Hiramatsu N. Ohkawa, K., Oze, T., Inoue, Y., Kurokawa, M., Yakushijin, T., Igura, T., Kiso, S., Kanto, T., Takehara, T., Tamura, S., Kasahara, A., Oshita, M., Hijioka, T., Katayama, K., Yoshihara, H., Hayashi, E., Imai, Y., Kato, M., HayashiKura
  • Journal Title: Hepatology Research 38 Pages: 450-456
  • NAID: 10024148320
  • Peer Reviewed
• [Journal Article] Repeated administration of recombinant human serum albumin caused no serious allergic reactions in patients with liver cirrhosis-a multicenter clinical study (2008)
  • Author(s): Kasahara A, Kita K., et al.
  • Journal Title: Journal of Gastroenterology 43 Pages: 464-472
  • NAID: 10021269192
  • Peer Reviewed
• [Journal Article] Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990-2003 (2008)
  • Author(s): Tanaka H., Imai Y., et al.
  • Journal Title: Annals of Internal Medicine 148 Pages: 820-826
  • Peer Reviewed
• [Journal Article] Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer : A novel approach for the development of tumor markers. (2008)
  • Author(s): Nakano M., Nakagawa T., et al.
  • Journal Title: International Journal of Cancer 122 Pages: 2301-2309
  • Peer Reviewed
• [Journal Article] Impaired cytokine response in myeloid dendritic cells in chronic hepatitis C virusinfection regardless of enhanced expression of Toll-like receptors and retinoic acid inducible gene-I (2008)
  • Author(s): Miyazaki M., Kanto T., et al.
  • Journal Title: Journal of Medical Virology 80 Pages: 980-988
  • Peer Reviewed
• [Journal Article] Virus associated innate immunity in liver. (2008)
  • Author(s): Kanto T.
  • Journal Title: Frontiers in Bioscience 13 Pages: 6183-6192
  • Peer Reviewed
• [Journal Article] Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C (2008)
  • Author(s): Hiramatsu N. Kurashige N, et al.
  • Journal Title: Hepatology Research 38 Pages: 52-59
  • NAID: 10020116973
  • Peer Reviewed
• [Journal Article] Glycomic Analysis of Alpha-Fetoprotein L3 in Hepatoma Cell Lines and Hepatocellular Carcinoma Patients. (2008)
  • Author(s): Nakagawa T., Miyoshi E., et al.
  • Journal Title: Journal of Proteome Research 7 Pages: 2222-2233
  • Peer Reviewed
• [Journal Article] Initial viral response is the most powerful predictor of the emergence of YMDD mutant virus in chronic hepatitis B patients treated with lamivudine. (2008)
  • Author(s): Kurashige, N., Hiramatsu, N., et. al.
  • Journal Title: Hepatology Research (In press)
  • NAID: 10024148320
  • Peer Reviewed
• [Journal Article] Impaired cytokine response in myeloid dendritic cells in chronic hepatitis C virus infection regardless of enhanced expression of Toll-like receptors and retinoic acid inducible gene-I (2008)
  • Author(s): Miyazaki M., Kanto T., et. al.
  • Journal Title: Journal of Medical Virology (In press)
  • Peer Reviewed
• [Journal Article] Impaired ability of interferon-alpha-primed dendritic cells to stimulate Th1-type CD4 T cell response in chronic hepatitis C virus infection (2007)
  • Author(s): Miyatake H., Kanto T., Inoue, M., Sakakibara, M., Kaimori, A., Yakushijin, T., Itose, I., Miyazaki, M., Kuzushita, N., Hiramatsu, N., Takehara, T., Kasahara, A., Hayashi, N.
  • Journal Title: Journal of Viral Hepatitis 14 Pages: 404-412
  • Peer Reviewed
• [Journal Article] Involvement of dendritic cell frequency and function in virological relapse in pegylated interferon-α2b and ribavirin therapy for chronic hepatitis C patients (2007)
  • Author(s): Itose I., Kanto T., Inoue, M., Miyazaki, M., Miyatake, H., Sakakibara, M., Yakushijin, T., Oze, T., Hiramatsu, N., Takehara, T., Kasahara, A., Hayashi, N.
  • Journal Title: ournal of Medical Virology 79 Pages: 511-521
  • Peer Reviewed
• [Journal Article] Innate immunity in hepatitis C virus infection: Interplay amongdendritic cells, natural killer cells and natural killer T cells (2007)
  • Author(s): Jinushi, M., Takehara, T., Tatsumi, T., Yamaguchi, S., Sakamori, R., Hiramatsu, N., Kanto, T., Ohkawa, K., Hayashi, N
  • Journal Title: Hepatolgy Reseach 37 Suppl 3S Pages: 319-326
  • NAID: 10019796655
  • Peer Reviewed
• [Journal Article] Natural killer cell and hepatic cell interaction via NKG2A leads to dendritic cell-mediated induction of CD4 CD25 T cells with PD-1-dependent regulatory activities Immunology (2007)
  • Author(s): Jinushi, M., Takehara, T., Tatsumi, T., Yamaguchi, S., Sakamori, R., Hiramatsu, N., Kanto, T., Ohkawa, K., Hayashi, N
  • Journal Title: 120 Pages: 73-82
  • Peer Reviewed
• [Journal Article] Impaired ability of interferon-alpha-primed dendritic cells to stimulate Th1-type CD4 T cell response in chronic hepatitis C virus infection. (2007)
  • Author(s): Miyatake H., Kanto T., et. al.
  • Journal Title: Journal of Viral Hepatitis 14 Pages: 404-412
  • Peer Reviewed
• [Journal Article] Involvement of dendritic cell frequency ahd function in virological relapse in pegylated interferon-α2b and ribavirin therapy for chronic hepatitis C patients. (2007)
  • Author(s): Itose I., Kanto T., et. al.
  • Journal Title: Journal of Medical Virology 79 Pages: 511-521
  • Peer Reviewed
• [Journal Article] Innate immunity in hepatitis C virus infection: Interplay amongdendritic cells, natural killer cells and natural killer T cells. (2007)
  • Author(s): Kanto, T. and Hayashi, N.
  • Journal Title: Hepatolgy Reseach 37 Suppl 3
  • NAID: 10019796655
  • Peer Reviewed
• [Journal Article] Natural killer cell and hepatic cell interaction via NKG2A leads to dendritic cell-mediated induction of CD4 CD25 T cells with PD-1-dependent regulatory activities (2007)
  • Author(s): Jinushi, M., Takehara, T., et. al.
  • Journal Title: Immunology 120 Pages: 73-82
  • Peer Reviewed
• [Presentation] Dynamics of plasmacytoid dendritic cells as a predictor of relapse regardless of virological response in pegylated interferon-a and ribavirin therapy in chronic hepatitis C patients (2009)
  • Author(s): Kanto T
  • Organizer: The Liver Meeting AASLD 60th Annual Meeting and Postgraduate Course
  • Place of Presentation: Boston, MA, USA
• [Presentation] Feasibility of IL-10-producing regulatory Type 1 cells for the monitoring of viable hepatocellular carcinoma through local ablation therapy (2009)
  • Author(s): Kakita N, Kanto T
  • Organizer: The Liver Meeting AASLD 60th Annual Meeting and Postgraduate Course
  • Place of Presentation: Boston, MA, USA
• [Presentation] Myeloid dendritic cells as a therapeutic target for immune restoration by HCV NS3 protease inhibitor in chronic hepatitis C patients (2009)
  • Author(s): Miyazaki M, Kanto T
  • Organizer: The Liver Meeting AASLD 60th Annual Meeting and Postgraduate Course
  • Place of Presentation: Boston, MA, USA
• [Presentation] Reduced drug doses in genotype 1 patients with chronic hepatitis C during treatment with pegylated interferon alfa-2B plus ribavirin delays the timing of HCVRNA negativity or prevents its attainment; A propensity score-matched study (2009)
  • Author(s): Son C, Hiramatsu N
  • Organizer: he Liver Meeting AASLD 60th Annual Meeting and Postgraduate Course
  • Place of Presentation: Boston, MA, USA
• [Presentation] Prediction of early response to pegylated interferon and ribavirin in chronic hepatitis C based on amino acid substitutions in the viral core region (2009)
  • Author(s): Inoue Y, Hiramatsu N
  • Organizer: The Liver Meeting AASLD 60th Annual Meeting and Postgraduate Course
  • Place of Presentation: Boston, MA, USA
• [Presentation] Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alfa-2B and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses (2009)
  • Author(s): Inoue Y, Hiramatsu N
  • Organizer: The Liver Meeting AASLD 60th Annual Meeting and Postgraduate Course
  • Place of Presentation: Boston, MA, USA
• [Presentation] Reduced drug doses in genotype 1 patients with chronic hepatitis C during treatment with pegylated interferon alfa-2B plus ribavirin delays the timing of HCVRNA negativity or prevents its attainment ; A propensity score-matched study (2009)
  • Author(s): Son C, Hiramatsu N, et al.
  • Organizer: The American Association for the Study of Liver Diseases 60^<th> Annual Meeting and Postgraduate Course
  • Place of Presentation: Boston MA, USA
• [Presentation] Prediction of early response to pegylated interferon and ribavirin in chronic hepatitis C based on amino acid substitutions in the viral core region (2009)
  • Author(s): Inoue Y, Hiramatsu N, et al.
  • Organizer: The American Association for the Study of Liver Diseases 60^<th> Annual Meeting and Postgraduate Course
  • Place of Presentation: Boston MA, USA
• [Presentation] Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alfa-2B and ribavirin : reducing drug doses has no impact on rapid and sustained virological responses (2009)
  • Author(s): Inoue Y, Hiramatsu N., et al.
  • Organizer: The American Association for the Study of Liver Diseases 60^<th> Annual Meeting and Postgraduate Course
  • Place of Presentation: Boston MA, USA
• [Presentation] Dynamics of plasmacytoid dendritic cells as a predictor of relapse regardless of virological response in pegylated interferon-a and ribavirin therapy in chronic hepatitis C patients (2009)
  • Author(s): Kanto T, Itose I, et al.
  • Organizer: The American Association for the Study of Liver Diseases 60^<th> Annual Meeting and Postgraduate Course
  • Place of Presentation: Boston MA, USA
• [Presentation] Myeloid dendritic cells as a therapeutic target for immune restoration by HCV NS3 protease inhibitor in chronic hepatitis C patients (2009)
  • Author(s): Miyazaki M, Kanto T, et al.
  • Organizer: The American Association for the Study of Liver Diseases 60^<th> Annual Meeting and Postgraduate Course
  • Place of Presentation: Boston MA, USA
• [Presentation] Feasibility of IL-10-producing regulatory Type 1 cells for the monitoring of viable hepatocellular carcinoma through local ablation therapy (2009)
  • Author(s): Kakita N, Kanto T, et al.
  • Organizer: The American Association for the Study of Liver Diseases 60^<th> Annual Meeting and Postgraduate Course
  • Place of Presentation: Boston MA, USA
• [Presentation] Natural regulatory T cells as biomarker for the assessment of hepatocellular carcinoma in local ablation therapy (2008)
  • Author(s): Kakita N., Kanto T., et al
  • Organizer: The 59^<th> Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
  • Place of Presentation: San Francisco, CA. USA
  • Year and Date: 2008-11-03
• [Presentation] Dynamic changes of regulatory T cell subsets in patients with chronic HCV infection in relation to the degree of liver inflammation (2008)
  • Author(s): Itose I., Kanto T
  • Organizer: The 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
  • Place of Presentation: San Francisco, CA. USA
  • Year and Date: 2008-11-02
• [Presentation] IL-7 as a booster of Th2-differentiation by modulating myeloid dendritic cells in chronic hepatitis C virus infection (2008)
  • Author(s): Takebe S., Kanto T
  • Organizer: The 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
  • Place of Presentation: San Francisco, CA. USA
  • Year and Date: 2008-11-02
• [Presentation] Natural regulatory T cells as biomarker for the assessment of hepatocellular carcinoma in local ablation therapy (2008)
  • Author(s): Kakita N., Kanto T
  • Organizer: The 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
  • Place of Presentation: San Francisco, CA. USA
  • Year and Date: 2008-11-02
• [Presentation] Effect of interferon alfa-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis (2008)
  • Author(s): Kurokawa M., Hiramatsu N
  • Organizer: The 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
  • Place of Presentation: San Francisco, CA. USA
  • Year and Date: 2008-11-02
• [Presentation] Extended treatment with peginterferon alfa-2b and ribavirin combination therapy can suppress the relapse rate after treatment of chronic hepatitis C genotype 1 patients with late viral relapse (2008)
  • Author(s): Oze T., Hiramatsu N
  • Organizer: The 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
  • Place of Presentation: San Francisco, CA. USA
  • Year and Date: 2008-11-02
• [Presentation] Ribavirin dosage reduction raises relapse rate dose-dependently in genotype 1 patients with chronic hepatitis C responding to pegylated interferon alfa-2b plus ribavirin (2008)
  • Author(s): Oze T., Hiramatsu N
  • Organizer: The 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
  • Place of Presentation: San Francisco, CA. USA
  • Year and Date: 2008-11-02
• [Presentation] Dynamic changes of regulatory T cell subsets in patients with chronic HCV infection in relation to the degree of liver inflammation (2008)
  • Author(s): Itose I., Kanto L, et al
  • Organizer: The 59^th Annual Meeting of the American Associationfor the Study of Liver Diseases (AASLD)
  • Place of Presentation: San Francisco, CA. USA
  • Year and Date: 2008-11-02
• [Presentation] IL-7 as a booster of Th2-differentiation by modulating myeloid dendritic cells in chronic hepatitis C virus infection (2008)
  • Author(s): Takebe S., Kanto T., et al
  • Organizer: The 59^<th> Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
  • Place of Presentation: San Francisco, CA. USA
  • Year and Date: 2008-11-02
• [Presentation] Effect of interferon alfa-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis (2008)
  • Author(s): Kurokawa M., Hiramatsu N., et al
  • Organizer: The 59^<th> Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
  • Place of Presentation: San Francisco, CA. USA
  • Year and Date: 2008-11-02
• [Presentation] Extended treatment with peginterferon alfa-2b and ribavirin combination therapy can suppress the relapse rate after treatment of chronic hepatitis C genotype 1 patients with late viral relapse (2008)
  • Author(s): Oze T., Hiramatsu N., et al
  • Organizer: The 59^<th> Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
  • Place of Presentation: San Francisco, CA. USA
  • Year and Date: 2008-11-02
• [Presentation] Ribavirin dosage reduction raises relapse rate dose-dependently in genotype 1 patients with chronic hepatitis C responding to pegylated interferon alfa-2b plus ribavirin (2008)
  • Author(s): Oze T., Hiramatsu N., et al
  • Organizer: The 59^<th> Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
  • Place of Presentation: San Francisco, CA. USA
  • Year and Date: 2008-11-02
• [Presentation] NK and NKT-dendritic cell interactions in HCV infection (2008)
  • Author(s): Kanto T.
  • Organizer: Hepatic Inflammation and Immunity 2008
  • Place of Presentation: Galveston, Texas USA
  • Year and Date: 2008-01-27
• [Presentation] Dendritic cell as a versatile controller of innate and adaptive immune response against hepatitis C virus (2008)
  • Author(s): Kanto T
  • Organizer: The 10th International Symposium on Dendritic Cells
  • Place of Presentation: Kobe, Japan
• [Presentation] Impaired TLR/RIG-I-mediated innate immunity in myeloid dendritic cells in chronic hepatitis C patients (2008)
  • Author(s): Miyazaki M. Kanto T
  • Organizer: The 10th International Symposium on Dendritic Cells
  • Place of Presentation: Kobe, Japan
• [Presentation] Involvement of regulatory T cell dynamics in the achievement of biochemical response in 48-week PEG-IFNα2b and ribavirin combination therapy for chronic he patitis C patients (2007)
  • Author(s): Itose I., Kanto T., et. al.
  • Organizer: The 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
  • Place of Presentation: Boston, MA. USA
  • Year and Date: 2007-11-03
• [Remarks]
  • URL: http://www.med.osaka-u.ac.jp/pub/gh/index.htm
• [Remarks]
  • URL: http://www.med.osaka-u.ac.jp/pub/gh/index.htm
• [Remarks]
  • URL: http://www.med.osaka-u.ac.jp/pub/gh/index.htm
• [Remarks]
  • URL: http://www.med.osaka-u.ac.jp/pub/gh/index.htm